Elaboration of a model for predicting efficacy of monoclonal antibodies (cetuximab and bevacizumab) in patients with colorectal cancer and liver metastases.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Cetuximab
- Indications Colorectal cancer
- Focus Therapeutic Use
- 09 Feb 2009 Biomarkers information updated
- 22 Jun 2008 The expected completion date for this trial is now 1 Feb 2009 as reported by ClinicalTrials.gov.
- 22 Oct 2006 New trial record.